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abstractOBJECTIVES: The youngest children in a classroom are at increased risk of being medicated for
attention-deficit/hyperactivity disorder (ADHD). We examined the association between
children’s birth month and ADHD medication rates in Finland.
METHODS: Using a population-based study, we analyzed ADHD medication use among children
born in 2005 to 2007. Cases (n = 7054) were identified from the first purchase of medication
for ADHD. Cox proportional hazard models and hazard ratios (HRs) were examined by birth
month and sex. Finnish children start first grade in the year of their seventh birthday. The
cutoff date is December 31.
RESULTS: Risk of ADHD medication use increased throughout the year by birth month (ie,
January through April to May through August to September through December). Among boys
born in September to December, the association remained stable across cohorts (HR: 1.3; 95%
confidence interval [CI]: 1.1–1.5). Among girls born in September to December, the HR in the
2005 cohort was 1.4 (95% CI: 1.1–1.8), whereas in the 2007 cohort it was 1.7 (95% CI:
1.3–2.2). In a restricted follow-up, which ended at the end of the year of the children’s eighth
birthday, the HRs for boys and girls born in September to December 2007 were 1.5 (95% CI:
1.3–1.7) and 2.0 (95% CI: 1.5–2.8), respectively.
CONCLUSIONS: Relative immaturity increases the likelihood of ADHD medication use in Finland.
The association was more pronounced during the first school years. Increased awareness of
this association is needed among clinicians and teachers.
WHAT’S KNOWN IN THIS SUBJECT: The relative age
effect (RAE) in attention-deficit/hyperactivity disorder
(ADHD) indicates that ADHD medication use is more
common in the relatively youngest children within
a school grade. Within-country sex differences in ADHD
medication use vary and are among the largest in
Finland.
WHAT THIS STUDY ADDS: This population-based study
reveals that the RAE in ADHD medication use among
children was more pronounced during the first school
years (ages 6–8). The RAE in ADHD medication was
stable among boys across 3 cohorts but increasing
among girls.
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Attention-deficit/hyperactivity
disorder (ADHD) is a common
neurodevelopmental condition
characterized by age-inappropriate
levels and persistent patterns of
inattention or hyperactivity-
impulsivity or both, which interferes
with social functioning and
development.1,2 ADHD is recognized
as a lifelong disorder.3,4 Prevalence of
ADHD is estimated to be ∼5% in
children.2,5 However, the relative age
effect (RAE) refers to the fact that the
youngest children in classrooms are
more likely to receive a diagnosis and
be prescribed medication for ADHD
than their relatively older
classmates.6–8 Researchers of
previous studies have indicated that
relative age plays a more important
role with ADHD symptoms than the
season of birth,8,9 particularly during
childhood.10 One line of research
suggests that RAE may represent
a situation in which the more
immature behavior of younger
children is treated as ADHD.11–13
There is empirical evidence of the
RAE from countries with high
prescription rates, such as Iceland,14
the United States,15 Canada,16 and
Sweden,17 but also from countries
with moderate rates, such as
Norway18 and Taiwan.19
The strength of the RAE may vary
within countries across time. A
Danish study found evidence for an
RAE between 2000 and 2004,20
which then diminished during study
years 2006 to 2012.20,21 These
findings are possibly explained by the
fact that ∼40% of the relatively
younger children are held back one
year in the Danish school system.20,22
The fact that the RAE is associated
with school entry regulations further
implies that the effect size may
depend on the duration of the follow-
up.23 This is an under-researched
perspective.17 There is also notable
variation between countries in
prescribing rates for ADHD, and
studies also differ by the years
studied.6,24 For example, prevalence
rates of ADHD medication use among
the child population in Finland have
been relatively low, particularly
among girls,24,25 but the rates of
ADHD diagnoses and medication use
are increasing relatively rapidly.26 Sex
differences are also important to
consider because the rates of ADHD
vary by sex in middle childhood.
Emotion dysregulation and
externalizing behaviors drive referral
for ADHD.27,28 However, in recent
studies on sex differences, it has been
indicated that emotional and
behavioral difficulties are stronger
predictors of ADHD diagnosis in girls
when compared with boys.29,30 In
addition, girls with externalizing
symptoms are more likely to have
a referral for ADHD at a younger age
compared with boys with similar
behaviors.30 Interestingly, the
findings with regard to sex
differences in the RAE have been
inconclusive.14,16,18,20 This may relate
to the fact that sex differences in
ADHD medication use vary between
countries. In a recent study in which
worldwide ADHD medication use in
children was examined, the male-to-
female ratio in medication use was
the highest in Finland.24
Our purpose with this study was to
examine the extent to which relative
age is associated with ADHD
medication use among children in
Finland born in 2005 to 2007.
Importantly, we were able to use the
study by Sayal et al,13 which
examined the association between
relative age and an ADHD diagnosis
among Finnish children (born
between 1991 and 2004) as
a baseline. Altogether, with our study,
we add to the global understanding of
the RAE in ADHD by providing
a more-complete picture of the
phenomenon from a single
jurisdiction where the rates of
children with ADHD have increased
somewhat rapidly and delayed school
entry has decreased.13,26 First, we
hypothesized that with delayed
school entry being somewhat rare in
Finland, there would be at least
a modest RAE in prescribing ADHD
medication for children. Second, given
that difference in maturity is more
extreme at young ages, we expected
that the RAE in ADHD medication use
would be stronger at ages 6 to 7,
when children start primary
education. Third, because of the
prominent sex differences in the rates
of ADHD, we expected that the RAE
would be different in boys and girls.
METHODS
Study Setting and Data Sources
The study outcome was ADHD
medication prescribing. All
permanent residents of Finland are
covered under the National Health
Insurance system. Reimbursements
for medical expenses are available for
products that the Pharmaceuticals
Pricing Board has confirmed as
reimbursable. A particular medicine
can only be reimbursed with respect
to specific medical indications noted
in the summary of product
characteristics. For example, children
are eligible for reimbursements for
the costs of ADHD prescription
medication when the prescription
indication is ADHD. Reimbursements
from all Finnish pharmacies are
recorded in the National Prescription
Register maintained by the Social
Insurance Institution. The register
contains information on the child’s
birth date and sex and the
prescription dispensing date.
Although the register does not
include information on ADHD
diagnoses, all children presumably
had an adequate diagnosis of ADHD
before a medication prescription was
dispensed.
Study Population and ADHD
Medication Use
ADHD medication use was examined
by age-, sex-, and birth
month–matched population, with
follow-up data from children born in
2005, 2006, and 2007 with
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permanent residence in Finland (N =
182802) at the end of December 31,
2017. The children were followed
from their sixth birthday until the end
of calendar years of their 12th (born
2005), 11th (born 2006), or 10th
(born 2007) birthday.
The first purchase of medication for
ADHD was the main outcome.
Altogether, 7054 cases with
medication were identified.
Medication for ADHD included all the
substances reimbursable in Finland
within the category of centrally acting
sympathomimetic drugs according to





of ADHD medication use was defined
as the number of children who had at
least one reimbursed purchase of
ADHD medication compared with the
number of children in the total
population.
Relative Age
Children were classified into 3 groups
depending on their month of birth:
the oldest were born in January to
April, the middle group in May to
August, and the relatively youngest in
September to December. Finnish
children must attend kindergarten
(refers to a preprimary education in
Finland) for one year before
compulsory basic education begins.
The cutoff date for school eligibility is
December 31. Children start
kindergarten in the calendar year of
their sixth birthday and first grade of
comprehensive school (basic
education) in the year of their
seventh birthday. The school year
starts in mid-August. Although
delayed school entry is possible, this
is a relatively uncommon procedure,
and the number of children whose
school entry is delayed is decreasing.
According to Statistics Finland (V.
Hämäläinen, personal
communication, 2019), 1100 children
were held back one year in 2010
(875, 713, and 698 children in 2012,
2013, and 2014, respectively).
Furthermore, delayed entry into
primary education because of
inattention and hyperactivity deficits
is rare. Instead, children are expected
to receive either special or intensified
support at school if needed.
Statistical Analyses
The time of the first ADHD medication
purchase was analyzed by a series of
sex-stratified Cox proportional hazards
regression models by using right
censoring.31 The follow-up ended on
December 31, 2017. Children born in
the first months of the calendar year
were set as a reference group.
Inspection of log-minus-log survival
curves did not indicate a violation of
the proportional hazard assumption.
For sensitivity analyses, we further
assessed whether hazard ratios (HRs)
change over time. Regarding use of
medication, it is possible that children
born in January to April will later move
toward their classmates born in
September to December, which would
result in different HRs depending on
the duration of the study.17,23 In
a restricted model, the follow-up ended
in the year of the children’s eighth
birthday. In additional analyses, we also
examined incidence rate ratios (IRRs).
This relates to the fact that children
born in September to December are
relatively close in age compared with
children born in January to April in the
following year. Pairwise comparisons
were examined for children born in
September to December 2005 and
2006 relative to children born in
January to April 2006 and 2007.
Analyses were performed by using
SPSS version 25 (IBM SPSS Statistics,
IBM Corporation) and the computing
environment R (ggplot2 package).
RESULTS
Cumulative Proportions of ADHD
Medication Use
The study population included
182802 Finnish children born in
2005 to 2007 (93 374 boys, 89 428
girls). By the end of follow-up, 7054
children had received ADHD
medication at least once (5775 boys,
1279 girls). Cumulative proportions
for ADHD medication use in boys and
girls born in 2005 to 2007 are shown
in Fig 1. Cumulative proportions
increased somewhat steadily until age
9 and then started to slow down
across both sexes. At the end of
follow-up (December 31, 2017), 5.9%
to 6.4% of boys and 1.4% to 1.6% of
girls had at least 1 reimbursed
purchase of ADHD medication.
In Cox regression analyses, it was
shown that the HRs for boys (Table 1)
were somewhat stable across cohorts.
For boys born in May to August (HRs
∼1.1–1.2) and September to
December (HRs ∼1.3), ADHD
medication use was more common
compared with those born in January
to April. Among girls born in either
May to August or September to
December 2005, the HRs were 1.3
and 1.4, respectively, when compared
with those born between January and
April. Among girls born in either May
to August or September to December
2007, the HRs were 1.6 and 1.7,
respectively. After restricting the
follow-up to the year of the children’s
eighth birthday, the RAE became
more pronounced (Tables 1 and 2).
Among boys born in May to August
and September to December, the HRs
were 1.2 to 1.3 and 1.5 to 1.7,
respectively, compared with those
born in January to April. Among girls,
HRs for later-born children (born in
May to August and September to
December) were 1.7 to 1.9 and 2.0 to
2.1, respectively, compared with their
early-born peers (January to April).
Incidence Ratios in ADHD Medication
Use by Birth Month
ADHD medication incidence per 1000
persons across 3 cohorts are
presented in Tables 3 and 4. Further
analyses showed that incidence ratios
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were significant in the years of
primary education entry. After
comparing boys (Table 3) born at the
end of years 2005 and 2006 (ie,
September to December) and who are
relatively close in age with children
born in the first months of the
following calendar years, the IRRs at
age 6 (ie, the year of kindergarten
entry) were 1.8 and 1.7, whereas the
IRRs at age 7 were 1.4. In girls
(Table 4), the corresponding analyses
yielded significant IRRs at age 7 (IRRs
2.5 and 2.8), when children enter
school. IRR estimates were .1 for
each age interval. This indicates that
there was no catch-up effect among
those born in January to April.
DISCUSSION
With this study, we provide up-to-
date evidence for the association
between children’s birth month and
ADHD from a single jurisdiction. In
line with our hypothesis, our findings
reveal an association among children
between younger relative age in the
school year and receiving medication
for ADHD. The findings further reveal
that differences in maturity, which are
stronger at younger ages, moderate
the association between children’s
birth month and ADHD medication
use because the RAE was stronger
across sexes in the years of school
entry. We also observed that the RAE
in medication for ADHD seemed more
pronounced in the female population
than the male population.
Importantly, the comparison of 3
consecutive cohorts indicated that the
association between ADHD
medication use and relative age was
stable among the male population but
showed signs of increase among the
female population.
Our findings are consistent with
earlier studies on the influence of
relative age on the increased
likelihood of receiving ADHD
medication.6,7 The observed RAE
among children (born between 2005
and 2007) in our study also
corroborates the findings from the
Finnish study that revealed greater
cumulative incidence of clinically
diagnosed ADHD among relatively
younger children within the Finnish
male and female populations born
between 1991 and 2004.13 Most
importantly, along with the
aforementioned study, our findings
increase the understanding of the
RAE in ADHD by providing
a comprehensive picture of the
association within a single country.
Although researchers of previous
studies have suggested relatively low
prescribing rates for ADHD in
Finland,24 our results indicated that
the prevalence of ADHD medication
use has increased somewhat rapidly
among Finnish children. In our study,
we observed that 7.3% of boys born
in September to December in 2005
had received at least one reimbursed
ADHD medication purchase by the
end of follow-up, whereas in girls, the
comparable figure was 1.8%.
An important discovery that emerged
was that the RAE in ADHD among
Finnish children is particularly
prominent in the early school years.
This is in line with the results of
a Swedish study,17 whereas
a Norwegian study concluded that the
RAE increased from grade 3
onwards.18 The finding that the
relatively youngest children in
classrooms are more likely to be
FIGURE 1
Cumulative proportions of ADHD medication use across cohorts by sex.
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prescribed medication for ADHD than
their relatively older peers in the
years of school entry underscores the
notion that school entry regulations
may play an important role.7 For
example, children in Finland and
Denmark start first grade in the
calendar year of their seventh
birthday, and the cutoff date for
school eligibility in both countries is
December 31. However, in findings
from the Danish study, it is shown
that although the use of medication
for Danish children with ADHD had
increased during the years 2000 to
2012, the RAE on ADHD medication
use decreased and further vanished
during the aforementioned study
years.20 This may stem from the fact
that ∼40% of children born in
October to December are held back
one year in the Danish school
system.20–22 In Finland, delayed
school entry is rare and ever
decreasing. Meanwhile, the
prevalence of ADHD medication use
has increased steadily. Therefore, it is
possible that in countries with an
RAE, the more immature behavior of
younger children within the school
year is treated as ADHD.7,11 In line
with this notion, teacher ratings of
whether children display clinically
significant ADHD symptomology are
more strongly associated with
relative immaturity when compared
with parent ratings.15,17 In addition to
school entry regulations, we
speculate that the increased
availability and improved use of
school contingency management
could also protect from the RAE
among children with ADHD
susceptibility.27,28
Our findings indicate a large male-to-
female discrepancy in ADHD
medication use among the Finnish
child population. This was also
addressed in a recent retrospective
observational study in which
researchers examined trends in
ADHD medication use among children
in 13 countries.24 Furthermore, our
study findings extend previous
research by showing that the
association between relative age and
ADHD medication use is more
prominent among the female
population.7 This finding is in line
with studies from Canada16 and
Norway.18 In fact, the observed HRs
in the male and female populations
are similar to those of a Canadian
study.16 In comparison, researchers of
studies from Iceland,14 Denmark,21
and Sweden17 did not discover sex-
based differences. Regarding sex
differences, our findings indicate that
the prescribing rates for ADHD
medication among boys born toward
the end of the year are close to the
upper threshold of pooled estimates
of ADHD prevalence.5 Consequently,
there is less room for an increase in
ADHD medication use in boys
compared with girls. This might
explain why the RAE appeared to
remain stable in boys born in 2005
to 2007.
Additionally, because of a significant
sex discrepancy in ADHD medication
use, the average prevalence ratio
among girls is well below the
population average. We speculate
that over the long-term, as the
prevalence ratio among girls moves
closer to the population average, the
RAE may weaken.32 Another possible
explanation is that, at present,
different manifestations of ADHD may
go unnoticed in the female population
in Finland, and those with ADHD
medication are perhaps more likely to
suffer from co-occurring disorders,
TABLE 1 Risk of ADHD Medication Use Among Boys Born 2005–2007 by Birth Month
2005 2006 2007
Persons Cases With ADHD
Medication, n (%)
HR (95% CI) Persons Cases With ADHD
Medication, n (%)
HR (95% CI) Persons Cases With ADHD
Medication, n (%)
HR (95% CI)





9911 529 (5.3) 1 10 500 572 (5.4) 1 10 350 548 (5.3) 1
May to August 10 638 705 (6.6) 1.24*** (1.10–1.40) 10 822 665 (6.1) 1.13* (1.01–1.27) 10 927 652 (6.0) 1.13* (1.01–1.27)
September to
December
10 031 733 (7.3) 1.39*** (1.24–1.54) 10 092 704 (7.0) 1.29*** (1.16–1.45) 10 103 666 (6.6) 1.26***(1.12–1.41)
Follow-up at the end of




9911 225 (2.3) 1 10 500 306 (2.9) 1 10 350 322 (3.1) 1
May to August 10 638 350 (3.3) 1.27** (1.07–1.50) 10 822 362 (3.3) 1.15 (0.99–1.34) 10 927 422 (3.9) 1.25** (1.08–1.44)
September to
December
10 031 407 (4.4) 1.67*** (1.42–1.97) 10 092 423 (4.2) 1.45*** (1.25–1.68) 10 103 472 (4.7) 1.51*** (1.31–1.74)
Cox proportional hazards regression model. Cases include all the children who had $1 reimbursed purchase of ADHD medication by the end of follow-up (% = cumulative incidence). CI,
confidence interval; ref, reference category; —, not applicable.
*** P # .001
** P # .01
* P # .05.
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such as oppositional defiant disorder.
Recent studies on sex differences
indicate that emotional and
behavioral difficulties are stronger
predictors of ADHD diagnosis in girls
when compared with boys.29,30 There
is also evidence that emotional and
behavioral difficulties are also in
greater contrast to what is perceived
as normative functioning in girls
compared with boys.30 Interestingly,
researchers of one study
discovered that delayed school
entry improved, in particular,
social functioning among girls in
early school years.21
Nevertheless, there is a need for
studies in which
researchers examine the extent to
which relative age is associated
with long-term outcomes and
social functioning.
The main strength of our study is the
population-based design using
prescription register data that cover
all reimbursed outpatient ADHD
medication purchases in children.
However, it is important to
acknowledge that with our register-
based data, we could not rule out
whether the increased risk for ADHD
medication use among relatively
younger children relates to the
TABLE 2 Risk of ADHD Medication Use Among Girls Born 2005–2007 by Birth Month
2005 2006 2007
Persons No. Cases With ADHD
Medication (%)
HR (95% CI) Persons No. Cases With ADHD
Medication (%)
HR (95% CI) Persons No. Cases With ADHD
Medication (%)
HR (95% CI)
Total 29 528 459 (1.6) — 30 060 401 (1.3) — 29 840 419 (1.4) —
Follow-up at December
31, 2017
January to April (ref) 9753 122 (1.3) 1 10 004 99 (1.0) 1 9979 98 (1.0) 1
May to August 10 177 165 (1.6) 1.30* (1.03–1.64) 10 306 149 (1.4) 1.47** (1.14–1.89) 10 205 160 (1.6) 1.60*** (1.25–2.06)
September to
December
9598 172 (1.8) 1.44** (1.14–1.81) 9750 153 (1.6) 1.59*** (1.24–2.05) 9656 161 (1.7) 1.71*** (1.33–2.19)
Follow-up at the end of
year of eighth
birthday
January to April (ref) 9753 41 (0.4) 1 10 004 43 (0.4) 1 9979 55 (0.6) 1
May to August 10 177 72 (0.7) 1.69** (1.15–2.47) 10 306 82 (0.8) 1.85*** (1.28–2.68) 10 205 96 (0.9) 1.71** (1.23–2.38)
September to
December
9598 81 (0.8) 2.01*** (1.38–2.93) 9750 87 (0.9) 2.08*** (1.44–3.00) 9656 107 (1.1) 2.02*** (1.46–2.79)
Cox proportional hazards regression model. Cases include all the children who had $1 reimbursed purchase of ADHD medication by the end of follow-up (% = cumulative incidence). CI,
confidence interval; ref, reference category; —, not applicable.
*** P # .001
** P # .01
* P # .05.
TABLE 3 Incidence per 1000 Persons for ADHD Medication Among Boys Born 2005–2007 by Birth Month
Age,
y
No. Cases and Incidence (95% CI)
January to April
No. Cases and Incidence (95% CI) May
to August
No. Cases and Incidence (95% CI)
September to December
IRR (95% CI)











































































































































— — 43; 4.0
(3.0–5.4)
— — 17; 1.7
(1.1–2.7)
— — — —
IRRs are between boys born in the last third of the year (September to December) and boys born in the first third (January to April) of the following year. CI, confidence interval; —, not
applicable.
a IRR is significant at P , .05.
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misidentification of ADHD or perhaps
to the fact that relative immaturity
aggravates ADHD traits. Nevertheless,
the empirical findings support the
idea that school entry plays an
important role. Further studies with
better used information from various
national registers and adjustment for
confounding factors are needed to
examine the extent to which the RAE
is associated with medication use and
diagnoses and whether ADHD
presentations moderate the RAE.
Importantly, as the Finnish Current
Care Guideline of ADHD enhances the
notion that it is pivotal to assess
children’s symptomology relative to
age, clinicians have become more
aware of the RAE in ADHD. Therefore,
it is important to replicate our
analyses in children born after 2007
in the near future to examine the
extent to which increased awareness
is associated with standards in
prescribing for children with ADHD.
CONCLUSIONS
With our study, we provide evidence
that children born in May to August
and September to December (ie,
relatively younger children in
a school class) are more likely to
receive ADHD medication in Finland
compared with children born in
January to April. The risk of a modest
RAE was stable among boys but
appeared to be increasing among
girls. These findings may stem from
the fact that ADHD medication use
among boys has become common in
Finland, whereas ADHD medication
use among girls is still relatively low.
The RAE in ADHD medication use was
more pronounced in the years when
children enter school. Therefore,
there is a need to consider school
entry regulations and, particularly,
increase the availability of school
contingency management programs
to reduce the RAE. Importantly, there
is a need for prospective studies in
which researchers examine whether
relative age is associated with youth






IRR: incidence rate ratio
RAE: relative age effect
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TABLE 4 Incidence per 1000 Persons for ADHD Medication Among Girls Born 2005–2007 by Birth Month
Age,
y
No. Cases and Incidence (95% CI)
January to April
No. Cases and Incidence (95% CI)
May to August
No. Cases and Incidence (95% CI)
September to December
IRR (95% CI)
2005 2006 2007 2005 2006 2007 2005 2006 2007 2005 September to
December versus
2006 January to April
2006 September to
December versus












































































































— 2.09 (1.13–3.97)a —
12 18; 1.9
(1.1–2.9)
— — 14; 1.4
(0.8–2.3)
— — 4; 0.4
(0.1–1.0)
— — — —
IRR are between girls born in the last third of the year (September to December) and girls born in the first third (January to April; reference category) of the following year. CI, confidence
interval; —, not applicable.
a IRR is significant at P , .05.
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